Picture of Tvardi Therapeutics logo

TVRD — Tvardi Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Cara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

* Cara Therapeutics Inc  CARA.OQ  reported a quarterly
adjusted
loss of 37 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -58 cents.  The mean expectation of
five analysts for the quarter was for a loss of 27 cents per
share. Wall Street expected results to range from -35 cents
to -23 cents per share.
    * Revenue fell 85.7% to $991.00 thousand from a year ago;
analysts
expected $1.17 million. 
    * Cara Therapeutics Inc's reported EPS for the quarter was a
loss
of 37 cents​.
    * The company reported a quarterly loss of $20.02 million.
    * Cara Therapeutics Inc shares had risen by 27.4% this
quarter and
lost 55.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"

Wall Street's median 12-month price target for Cara Therapeutics
Inc is $1.01 
This summary was machine generated from LSEG data August 15 at
04:58 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -0.27          -0.37          Missed
 Mar. 31 2024      -0.40          -0.56          Missed
 Dec. 31 2023      -0.41          -0.59          Missed
 Sep. 30 2023      -0.52          -0.52          Met

Recent news on Tvardi Therapeutics

See all news